|
News for Healthier Living
ASCO: Pre-Surgical Combination Therapy Boosts Survival in Patients with Rare Thyroid Cancer
A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC) compared with historical controls, according to new research from The University of Texas MD Anderson Cancer Center.
May 31, 2025
June 14 2025June 13 2025June 12 2025June 11 2025June 10 2025June 9 2025June 8 2025June 7 2025June 6 2025June 5 2025June 4 2025June 3 2025June 2 2025June 1 2025
|
|
|
|
|